OTCGREY
TAISF

Taisho Pharmaceutical Holdings Co. Ltd

Prices are adjusted according to historical splits.

Taisho Pharmaceutical Holdings Co. Ltd Stock Price

Vitals

Today's Low:
$41.66
Today's High:
$41.66
Open Price:
$41.66
52W Low:
$35.55
52W High:
$43.25
Prev. Close:
$42
Volume:
1500

Company Statistics

Market Cap.:
$0
Book Value:
9780.781
Revenue TTM:
$313.11 billion
Operating Margin TTM:
8.57%
Gross Profit TTM:
$163.83 billion
Profit Margin:
5.62%
Return on Assets TTM:
1.8%
Return on Equity TTM:
2.53%

Company Profile

Taisho Pharmaceutical Holdings Co. Ltd had its IPO on under the ticker symbol TAISF.

The company operates in the sector and industry. Taisho Pharmaceutical Holdings Co. Ltd has a staff strength of 8,784 employees.

Stock update

Shares of Taisho Pharmaceutical Holdings Co. Ltd opened at $41.66 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $41.66 - $41.66, and closed at $41.66.

This is a -0.81% slip from the previous day's closing price.

A total volume of 1,500 shares were traded at the close of the day’s session.

In the last one week, shares of Taisho Pharmaceutical Holdings Co. Ltd have slipped by -0.81%.

Taisho Pharmaceutical Holdings Co. Ltd's Key Ratios

Taisho Pharmaceutical Holdings Co. Ltd has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Taisho Pharmaceutical Holdings Co. Ltd’s revenue was $313.11 billion with a gross profit of $163.83 billion and an EBITDA of $51.88 billion. The EBITDA ratio measures Taisho Pharmaceutical Holdings Co. Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Taisho Pharmaceutical Holdings Co. Ltd’s operating margin was 8.57% while its return on assets stood at 1.8% with a return of equity of 2.53%.

In Q3, Taisho Pharmaceutical Holdings Co. Ltd’s quarterly earnings growth was a negative -24.2% while revenue growth was a positive 17%.

Taisho Pharmaceutical Holdings Co. Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
35.5631
PEG

Its diluted EPS in the last 12-months stands at $1.181 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Taisho Pharmaceutical Holdings Co. Ltd’s profitability.

Taisho Pharmaceutical Holdings Co. Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Taisho Pharmaceutical Holdings Co. Ltd stock pays annual dividends of $100 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0
Total Liabilities
$67.57 billion
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Taisho Pharmaceutical Holdings Co. Ltd ended 2024 with $0 in total assets and $0 in total liabilities. Its intangible assets were valued at $0 while shareholder equity stood at $0.

Taisho Pharmaceutical Holdings Co. Ltd ended 2024 with $0 in deferred long-term liabilities, $67.57 billion in other current liabilities, 30000000000.00 in common stock, $709.76 billion in retained earnings and $0 in goodwill. Its cash balance stood at $0 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Taisho Pharmaceutical Holdings Co. Ltd’s total current assets stands at $391.97 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $55.78 billion compared to accounts payable of $14.88 billion and inventory worth $49.37 billion.

In 2024, Taisho Pharmaceutical Holdings Co. Ltd's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Taisho Pharmaceutical Holdings Co. Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$41.66
52-Week High
$43.25
52-Week Low
$35.55
Analyst Target Price
$

Taisho Pharmaceutical Holdings Co. Ltd stock is currently trading at $41.66 per share. It touched a 52-week high of $43.25 and a 52-week low of $43.25. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $39.75 and 200-day moving average was $47.96 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 4087% of the company’s stock are held by insiders while 1783.1% are held by institutions.

Frequently Asked Questions About Taisho Pharmaceutical Holdings Co. Ltd

The stock symbol (also called stock or share ticker) of Taisho Pharmaceutical Holdings Co. Ltd is TAISF

The IPO of Taisho Pharmaceutical Holdings Co. Ltd took place on

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The company offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. Further it provides Clarith, a macrolide antibiotic; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products, as well as engages in real estate leasing, management, possession, and operation. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is based in Tokyo, Japan.

Address

3-24-1 Takada, Tokyo, Japan, 170-8655